Valuation
- Market cap
- 3,000
- Revenue TTM
- $540,000
- Net income TTM
- $-5,020,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- -929.63%
- Debt to equity
- 0.00
Trading
- Volume
- 43,300
- Avg volume
- 30,492
- Day's range
- $0.00 – $0.00
- Shares out
- 4,621,000
- Stochastic %K
- 100%
- Beta
- 1.73
- Analysts
- —
- Price target
- $10.00
Company profile
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral l...
Show more
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. On March 30, 2026, Lipella Pharmaceuticals Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Western District of Pennsylvania.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 412 894 1853
- Website
- https://lipella.com
- Address
- 7800 Susquehanna St., Suite 505, Pittsburgh, United States
Latest news
No headlines yet.
